
Waters (WAT) Stock Forecast & Price Target
Waters (WAT) Analyst Ratings
Bulls say
Waters is well-positioned to benefit from improving demand in pharma manufacturing, with a strong track record of turning around underperforming businesses and successfully integrating large acquisitions. The recent merger with BD's life science and diagnostics business should bring significant growth and cost synergies, as well as expanding Waters' reach into the diagnostics and discovery-related life science tools market. Additionally, the company has a strong management team with a track record of successful turnarounds and acquisitions.
Bears say
Waters is facing multiple challenges that could negatively impact its growth potential and financial performance in the near future. The company's recent merger with BD's life science and diagnostics business has increased its exposure to diagnostics, which has been facing weakening industry trends. This increased concentration may dilute Waters' organic sales growth potential and also divert management's time and resources, hindering its ability to effectively address these challenges. Additionally, the company's high-margin consumables and service contracts may not be enough to sustain its resilient recurring revenue base if the demand for its products continues to decline in the academic and government markets.
This aggregate rating is based on analysts' research of Waters and is not a guaranteed prediction by Public.com or investment advice.
Waters (WAT) Analyst Forecast & Price Prediction
Start investing in Waters (WAT)
Order type
Buy in
Order amount
Est. shares
0 shares